Affiliation:
1. 1 Cleveland Clinic Akron General, Center for Family Medicine, Akron, Ohio.
2. 2 Northeast Ohio Medical University, Rootstown, Ohio.
Abstract
Prevalence of dementia continues to increase with limited pharmacotherapy options available. Acetylcholinesterase inhibitors remain a mainstay of treatment. The US FDA has approved three oral medications within this class— donepezil, galantamine, and rivastigmine. In 2022, the
US Food and Drug Administration approved a novel patch formulation for donepezil that could be beneficial for patients with dysphagia as well as potentially decreasing the side effect burden. The purpose of this analysis is to review the efficacy, safety, tolerability, and clinical considerations
related to this novel formulation.
Publisher
American Society of Consultant Pharmacists
Reference17 articles.
1. Epidemiology of Alzheimer's disease: occurrence, determinants, and strategies toward intervention
2. Alzheimer’s Association.
3. Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians.;Ann Intern Med.,2008
4. Meta-analysis of randomized controlled trials on the efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer’s disease.;Neuroscience.,2019
5. A systematic review and meta-analysis of the effectiveness of acetylcholinesterase inhibitors and memantine in treating the cognitive symptoms of dementia.;Dement Geriatr Cogn Disord.,2018